NASDAQ:HCWB

HCW Biologics (HCWB) Stock Forecast, Price & News

$1.97

-0.08 (-3.90%)

(As of 09/25/2023 ET)

Compare

Today's Range: $1.97
▼
$2.15
50-Day Range: $1.75
▼
$2.30
52-Week Range: $1.08
▼
$2.74

Volume: 9,011 shs
Average Volume: 10,336 shs
Market Capitalization: $70.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

HCW Biologics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 331.5% Upside
$8.50 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$46,489 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

149th out of 963 stocks

Pharmaceutical Preparations Industry

49th out of 451 stocks

3.5

Analyst's Opinion

Consensus Rating
HCW Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, HCW Biologics has a forecasted upside of 331.5% from its current price of $1.97.
Amount of Analyst Coverage
HCW Biologics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of HCW Biologics has been sold short.
Short Interest Ratio / Days to Cover
HCW Biologics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in HCW Biologics has recently decreased by 14.40%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
HCW Biologics does not currently pay a dividend.
Dividend Growth
HCW Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HCWB.

3.9

News and Social Media Coverage

News Sentiment
HCW Biologics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for HCW Biologics this week, compared to 0 articles on an average week.
Search Interest
3 people have searched for HCWB on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added HCW Biologics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HCW Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,489.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
45.30% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.79% of the stock of HCW Biologics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of HCW Biologics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of HCW Biologics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
HCW Biologics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About HCW Biologics (NASDAQ:HCWB) Stock

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

HCWB Price History

30 days | 90 days | 365 days | Advanced Chart

HCWB Stock News Headlines

September 21, 2023 | seekingalpha.com

HCW Biologics director Gary Winer buys shares worth $3.3k - filing

September 16, 2023 | finance.yahoo.com

Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc

September 26, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 9, 2023 | finance.yahoo.com

Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc

September 6, 2023 | finance.yahoo.com

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

August 18, 2023 | finance.yahoo.com

Insider Stock Buying Reaches US$845k On HCW Biologics

August 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Cochlear Limited (OtherCHEOF)

August 11, 2023 | finanznachrichten.de

HCW Biologics, Inc: HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

September 26, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Arrowhead Pharmaceuticals (ARWR)

August 11, 2023 | finance.yahoo.com

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

July 7, 2023 | finance.yahoo.com

The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable

July 1, 2023 | finance.yahoo.com

HCWB - HCW Biologics Inc.

June 16, 2023 | benzinga.com

Director at HCW Biologics Acquires Company Stock Options Worth 12,500 Shares

June 14, 2023 | baystreet.ca

HCW Gains on Patent News

June 14, 2023 | technews.tmcnet.com

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

June 14, 2023 | finance.yahoo.com

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

June 9, 2023 | benzinga.com

Chief Financial Officer of HCW Biologics Purchased $51K In Stock

June 8, 2023 | benzinga.com

HCW Biologics Chief Financial Officer Trades Company's Stock

May 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS) and HCW Biologics (HCWB)

May 10, 2023 | finance.yahoo.com

HCW Biologics First Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.057 loss in 1Q 2022)

May 9, 2023 | marketwatch.com

10-Q: HCW BIOLOGICS INC.

May 9, 2023 | msn.com

Recap: HCW Biologics Q1 Earnings

May 9, 2023 | msn.com

HCW Biologics: Q1 Earnings Insights

May 9, 2023 | finanznachrichten.de

HCW Biologics, Inc: HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

May 9, 2023 | finance.yahoo.com

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

April 27, 2023 | finance.yahoo.com

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

See More Headlines

Receive HCWB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter.

HCWB Company Calendar

Last Earnings: 8/11/2023
Today: 9/26/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HCWB
CUSIP: N/A
CIK: 1828673
Web: www.hcwbiologics.com
Phone: 954-842-2024
Fax: 954-842-2037
Employees: 44
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +331.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,900,000.00
Net Margins: N/A
Pretax Margin: -932.14%
Return on Equity: -53.51%
Return on Assets: -41.70%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 4.36
Quick Ratio: 4.36

Sales & Book Value

Annual Sales: $6.72 million
Price / Sales: 10.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.04 per share
Price / Book: 1.89

Miscellaneous

Outstanding Shares: 35,930,000
Free Float: 19,652,000
Market Cap: $70.78 million
Optionable: Not Optionable
Beta: 1.24

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Hing C. Wong Ph.D. (Age 69)
Founder, CEO, Director & Sec.
Comp: $421.05k

Ms. Rebecca Byam CPA (Age 67)
M.B.A., Chief Financial Officer
Comp: $297.08k

Dr. Peter Rhode Ph.D. (Age 65)
Chief Scientific Officer & VP of Clinical Operations
Comp: $248.57k

Ms. Nicole Valdivieso Esq.
VP of Legal Affairs

Ms. Raquel Diaz M.S.
Director of HR

Mr. Lee D. Flowers (Age 77)
Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HCWB Stock - Frequently Asked Questions

Should I buy or sell HCW Biologics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCW Biologics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HCWB shares.
View HCWB analyst ratings or view top-rated stocks.
What is HCW Biologics' stock price forecast for 2023?: 2 analysts have issued 12 month target prices for HCW Biologics' stock. Their HCWB share price forecasts range from $8.00 to $9.00. On average, they anticipate the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 331.5% from the stock's current price.
View analysts price targets for HCWB or view top-rated stocks among Wall Street analysts.
How have HCWB shares performed in 2023?: HCW Biologics' stock was trading at $1.9148 at the beginning of the year. Since then, HCWB stock has increased by 2.9% and is now trading at $1.97.
View the best growth stocks for 2023 here.
Are investors shorting HCW Biologics?: HCW Biologics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 21,400 shares, a decrease of 14.4% from the August 15th total of 25,000 shares. Based on an average trading volume of 11,300 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.1% of the shares of the company are short sold.
View HCW Biologics' Short Interest.
When is HCW Biologics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our HCWB earnings forecast.
How were HCW Biologics' earnings last quarter?: HCW Biologics Inc. (NASDAQ:HCWB) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.62 million for the quarter.

When did HCW Biologics IPO?: (HCWB) raised $45 million in an initial public offering (IPO) on Tuesday, July 20th 2021. The company issued 5,600,000 shares at a price of $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager.
What is HCW Biologics' stock symbol?: HCW Biologics trades on the NASDAQ under the ticker symbol "HCWB."
Who are HCW Biologics' major shareholders?: HCW Biologics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.14%). Insiders that own company stock include Gary M Winer, Hing C Wong, Jin-An Jiao, Lee Flowers, Rebecca Byam and Rick S Greene.
View institutional ownership trends.
How do I buy shares of HCW Biologics?: Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is HCW Biologics' stock price today?: One share of HCWB stock can currently be purchased for approximately $1.97.
How much money does HCW Biologics make?: HCW Biologics (NASDAQ:HCWB) has a market capitalization of $70.78 million and generates $6.72 million in revenue each year. The company earns $-14,900,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
How can I contact HCW Biologics?: The official website for the company is www.hcwbiologics.com. The company can be reached via phone at 954-842-2024, via email at mmcenroe@tiberend.com, or via fax at 954-842-2037.

This page (NASDAQ:HCWB) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial